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Special issue on the muscular dystrophies: Molecular basis
and therapeutic strategiesThe muscular dystrophies are a heterogeneous group of
inherited diseases characterized by progressive skeletal muscle
weakness and wasting, although a number of other tissues may be
affected. It is not surprising that experimental studies aimed at
revealing themolecular basis of variousmuscular dystrophies have
led to important insights into the functional organization of muscle
cells, including the discoveries of dystrophin and the dystroglycan
and sarcoglycan complexes. Perhaps more surprising is that
research on these disorders has revealed novel insights into nuclear
envelope structure and function and the impact of microsatellite
expansions and macrosatellite contractions on gene expression.
The objectives of this special issue are to review current
pathogenic mechanisms underlying the muscular dystrophies and
to discuss current and future therapeutic approaches. The first
section, which focuses on pathogenicmechanisms involved in the
muscular dystrophies, begins with a comprehensive review of
dystrophin (Duchenne/Becker) and its multiple interactions with
other sarcolemma-associated proteins (Ervasti). Another X-
linked disease, Emery–Dreifuss muscular dystrophy (EDMD),
is caused by mutations in the EMD gene that encodes the inner
nuclear membrane protein emerin. Interestingly, autosomal
dominant EDMD is caused by specific mutations in the LMNA
gene, andRoux andBurke discuss the fascinating question of how
mutations in emerin and lamin A/C lead to X-linked and
autosomal EDMD, respectively. Wasting of proximal shoulder
and pelvic girdle muscles is characteristic of the limb-girdle
muscular dystrophies (LGMDs), and LMNA mutations are also
associated with an autosomal dominant form of this disease,
LGMD1B.Although additional LGMDs are caused bymutations
in a number of sarcolemma-associated proteins (dysferlin, α-/β-/
γ-/δ-sarcoglycans, caveolin 3), Kramerova and colleagues
discuss how recessive mutations in CAPN3, which encodes the
cytosolic protease calpain 3, results in LGMD 2A. In contrast to
the LGMDs, the distal dystrophies, which begin with muscle
weakness in the hands, forearms, lower legs, or feet, are
attributable to mutations in genes encoding several sarcomeric
proteins, including myosin, titin, desmin, and dysferlin (Udd).
Next, Lisi and Cohn shift the focus to the congenital muscular
dystrophies (CDMs). Although these developmental diseases are
caused by mutations in components of the extracellular matrix
(laminin α2, collagen VI), sarcolemma (integrin α7), and
endoplasmic reticulum (selenoprotein-1), an increasing number
of CDMs have been linked to genes that regulate the glycosyla-0925-4439/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2007.01.001tion status of α-dystroglycan (LARGE, POMT1, POMT2,
FCMD, FKRP). The last three articles in this section review an
interesting set of muscle disorders caused by changes in
microsatellite and macrosatellite repeat number. Abu-Baker and
Rouleau provide an overview of PABPN1 (GCG)n expansions,
intranuclear PABPN1 protein aggregates, and their potential roles
in oculopharyngeal muscular dystrophy; van der Maarel and
coauthors discuss how D4Z4 macrosatellite contractions lead to
facioscapulohumeral muscular dystrophy; and Cho and Tapscott
focus on research showing that RNA-based mechanisms appear
to play a predominant role in myotonic dystrophy. In the second
section, the preceding articles on pathogenic mechanisms are
complemented by additional reviews on genetic models. Guyon
and colleagues discuss the isolation of zebrafish muscle mutants
and their use to evaluate pathogenic mechanisms and potential
therapies for muscular dystrophy. Phenotypic variability is a
common clinical feature ofmuscular dystrophy, andmousemodel
studies designed to evaluate the influence of genetic background
and modifiers are reviewed by Heydeman and colleagues.
The final two sections focus on current treatments and potential
new therapies. The third section includes articles on existing
treatment strategies for Duchenne muscular dystrophy (DMD)
(Wagner et al.) and a review of modern diagnostic tools for the
LGMDs (Bushby et al.). Odom and coauthors begin the final
section by reviewing recent progress on the use of viral-mediated,
particularly adeno-associated virus, gene therapy to ameliorate
dystrophic muscle changes. This special issue concludes with
reviews of alternative therapeutic strategies, including non-viral
(plasmid-mediated gene delivery, antisense oligonucleotide
induced exon skipping, oligonucleotide-mediated gene editing)
(Rando) and stem cell (Price et al.) approaches.
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